<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04334213</url>
  </required_header>
  <id_info>
    <org_study_id>A101_01DDI1927</org_study_id>
    <nct_id>NCT04334213</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150</brief_title>
  <acronym>CKD-383</acronym>
  <official_title>A Randomized, Open-label, Multiple-dose, Crossover Clinical Trial to Investigate the Pharmacokinetic Drug Interactions and Safety After Oral Administration of D745, D150 and CKD-501 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Clinical trial to investigate the pharmacokinetic drug interaction and safety of CKD-501,
      D745 and D150
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Open-label, Multiple-dose, Crossover Clinical Trial to Investigate the
      Pharmacokinetic Drug Interactions and Safety after Oral Administration of D745, D150 and
      CKD-501 in Healthy Adults
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2020</start_date>
  <completion_date type="Anticipated">July 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax,ss of CKD-501, D745, D150</measure>
    <time_frame>Day 1, Day 3, Day 4 - Pre-dose (0 hour) / Day 5 - Pre-dose (0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours</time_frame>
    <description>Cmax,ss: Maximum concentration of drug in plasma at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau,ss of CKD-501, D745, D150</measure>
    <time_frame>Day 1, Day 3, Day 4 - Pre-dose (0 hour) / Day 5 - Pre-dose (0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours</time_frame>
    <description>AUCtau,ss: Area under the plasma drug concentration-time curve within a dosing interval(τ) at steady state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss of CKD-501, D745, D150</measure>
    <time_frame>Day 1, Day 3, Day 4 - Pre-dose (0 hour) / Day 5 - Pre-dose (0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours</time_frame>
    <description>Cmin,ss: Minimum concentration of drug in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss of CKD-501, D745, D150</measure>
    <time_frame>Day 1, Day 3, Day 4 - Pre-dose (0 hour) / Day 5 - Pre-dose (0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours</time_frame>
    <description>Tmax,ss: Time to maximum plasma concentration at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLss/F of CKD-501, D745, D150</measure>
    <time_frame>Day 1, Day 3, Day 4 - Pre-dose (0 hour) / Day 5 - Pre-dose (0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours</time_frame>
    <description>CLss/F: Apparent Clearance at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluctuation of CKD-501, D745, D150</measure>
    <time_frame>Day 1, Day 3, Day 4 - Pre-dose (0 hour) / Day 5 - Pre-dose (0 hour), 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24 hours</time_frame>
    <description>Fluctuation: Peak trough fluctuation within one dosing interval</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days.
Period 2: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets). Period 2: CKD-501 - A single oral dose of 1 tablet under fasting conditions for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: D745, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D745: 1 tablet, D150: 2 tablets). Period 2: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: CKD-501, D745, D150 - A single oral dose of 4 tablets under fasting conditions for 5 days (CKD-501: 1 tablet, D745: 1 tablet, D150: 2 tablets). Period 2: D745, D150 - A single oral dose of 3 tablets under fasting conditions for 5 days (D745: 1 tablet, D150: 2 tablets).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-501</intervention_name>
    <description>QD, PO</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D745, D150</intervention_name>
    <description>QD, PO</description>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-501, D745, D150</intervention_name>
    <description>QD, PO</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult volunteers aged between 19 and 55-year-old

          2. Weight ≥ 55kg (men) or ≥ 50kg (women), with calculated body mass index(BMI) of 18.5 to
             27.0 kg/m2

          3. Women must meet one of the criteria written below:

               -  Menopause (No menstruation for 2 years)

               -  Sterilization (Hysterectomy or Oophorectomy, Tubal ligation etc.)

          4. Men agree to contraception &amp; won't donate sperm during the participation of clinical
             trial

          5. Those who voluntarily decide to participate and agree to comply with the cautions
             after hearing and fully understanding the detailed description of this clinical trial

        Exclusion Criteria:

          1. Those who have clinically significant disease or medical history of Hepatopathy, Renal
             dysfunction, Neurological disorder, Immunity disorder, Respiratory disorder,
             Genitourinary system disorder, Digestive system disorder, Endocrine system disorder,
             Cardiovascular disorder, Blood tumor, Psychical disorder, Severe urinary tract
             infection

          2. Those who have clinically significant dehydration or vulnerable to dehydration by poor
             oral intake

          3. Those who receive intravenous administration of radioactive iodine contrast agents
             (for intravenous urography, venous cholangiography, angiography, computed tomography
             using contrast agents, etc.) within 48 hours before the first administration of
             investigational product

          4. Those who have genetic problems such as galactose intolerance, Lapp lactose deficiency
             or glucose-galactose malabsorption

          5. Those who have past medical history of gastrointestinal disorder (Crohn's disease,
             ulcerative colitis, etc. except simple appendectomy or hernia surgery), which affect
             the absorption of drug

          6. Those who have history of hypersensitivity to active pharmaceutical ingredient
             (Lobeglitazone, Empagliflozin, Metformin) or additives.

          7. Those who have the test results written below

               -  AST, ALT &gt; 1.25 times higher than upper normal level

               -  Total bilirubin &gt; 1.5 times higher than upper normal level

               -  eGFR (estimated Glomerular Filtration Rate, which is calculated by MDRD) &lt; 60
                  mL/min/1.73m2

               -  &quot;Positive&quot; or &quot;Reactive&quot; test result of Hepatitis B &amp; C, HIV, RPR

               -  Under 5 min resting condition, systolic blood pressure &gt;150 mmHg or &lt;90 mmHg,
                  diastolic blood pressure &gt;100 mmHg or &lt;50 mmHg

          8. Those who have a drug abuse history within one year or positive reaction on urine drug
             screening test

          9. Those who received following drugs, which may affect results of clinical trial and
             safety Ethical-the-counter (ETC) drugs and herbal medicines within 14 days before the
             first administration of the investigational drug Over-the-counter (OTC) drugs, health
             foods and vitamin preparations within 7 days before the first administration of the
             investigational product

         10. Those who take barbiturate and related (causing induction or inhibition of metabolism)
             drug within 1 month before the first administration of investigational product

         11. Those who exceeding an alcohol and smoke consumption criteria or can't stop smoking,
             consuming alcohol and caffeine during hospitalization period Criteria: Caffeine &gt; 5
             cups/day, Alcohol &gt; 210 g/week, Smoke &gt; 10 cigarettes/day

         12. Those who took grapefruit before the first administration of investigational product
             or can't stop taking grapefruit during hospitalization period

         13. Those who received investigational product by participating in other clinical trial
             within 6 months before the first administration of investigational product

         14. Those who donated whole blood within 2 months or apheresis within 1 month

         15. Those who received transfusion within 1 month

         16. Those who are pregnant or breastfeeding

         17. Those who are deemed inappropriate to participate in clinical trial by investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Choon Ok Kim, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Choon Ok Kim, M.D., PhD.</last_name>
    <phone>+82-2-2228-0455</phone>
    <email>delivery98@yuhs.ac</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

